Go Pro
→ Trump Takes Emergency Action - Plus Elon Musk's New Venture (From Altimetry) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
$0.60
$0.60
$0.00
▼
$0.80
$35.79M1.7515,632 shsN/A
Anchiano Therapeutics Ltd. stock logo
ANCN
Anchiano Therapeutics
$1.71
+1.8%		$21.77
$0.51
▼
$10.55
$12.69M0.933.15 million shs30,960 shs
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
$1.11
$1.01
$0.38
▼
$19.19
$44.98M1.141.94 million shs602,221 shs
NanoViricides, Inc. stock logo
NNVC
NanoViricides
$1.52
$1.50
$0.85
▼
$2.23
$34.93M1.67559,574 shs132,941 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
0.00%0.00%0.00%0.00%+1,405.11%
Anchiano Therapeutics Ltd. stock logo
ANCN
Anchiano Therapeutics
0.00%0.00%0.00%0.00%+66.83%
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
0.00%-26.97%+54.60%+111.03%-32.32%
NanoViricides, Inc. stock logo
NNVC
NanoViricides
0.00%+2.70%+14.29%+16.92%-3.80%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
$0.60
$0.60
$0.00
▼
$0.80
$35.79M1.7515,632 shsN/A
Anchiano Therapeutics Ltd. stock logo
ANCN
Anchiano Therapeutics
$1.71
+1.8%		$21.77
$0.51
▼
$10.55
$12.69M0.933.15 million shs30,960 shs
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
$1.11
$1.01
$0.38
▼
$19.19
$44.98M1.141.94 million shs602,221 shs
NanoViricides, Inc. stock logo
NNVC
NanoViricides
$1.52
$1.50
$0.85
▼
$2.23
$34.93M1.67559,574 shs132,941 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
0.00%0.00%0.00%0.00%+1,405.11%
Anchiano Therapeutics Ltd. stock logo
ANCN
Anchiano Therapeutics
0.00%0.00%0.00%0.00%+66.83%
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
0.00%-26.97%+54.60%+111.03%-32.32%
NanoViricides, Inc. stock logo
NNVC
NanoViricides
0.00%+2.70%+14.29%+16.92%-3.80%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
0.00
N/AN/AN/A
Anchiano Therapeutics Ltd. stock logo
ANCN
Anchiano Therapeutics
0.00
N/AN/AN/A
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
0.00
N/AN/AN/A
NanoViricides, Inc. stock logo
NNVC
NanoViricides
3.00
Buy$6.00294.74% Upside

Current Analyst Ratings Breakdown

Latest ANCN, CPHI, ADXS, and NNVC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/6/2026
NanoViricides, Inc. stock logo
NNVC
NanoViricides
Noble Financial logo
Noble Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$6.00
7/6/2026
NanoViricides, Inc. stock logo
NNVC
NanoViricides
Noble Financial logo
Noble Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$6.00
(Data available from 8/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
$3.24M11.05N/AN/A($2.06) per share-0.29
Anchiano Therapeutics Ltd. stock logo
ANCN
Anchiano Therapeutics
N/AN/AN/AN/A$2.01 per shareN/A
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
$3.99M11.27N/AN/A$0.70 per share1.59
NanoViricides, Inc. stock logo
NNVC
NanoViricides
N/AN/AN/AN/A$0.66 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
-$48.07M-$5.02N/AN/AN/AN/AN/AN/AN/A
Anchiano Therapeutics Ltd. stock logo
ANCN
Anchiano Therapeutics
-$27.12M-$3.4611.40N/AN/AN/A36.08%27.40%N/A
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
-$3.08M-$0.55N/AN/AN/A-85.56%-63.93%-31.42%N/A
NanoViricides, Inc. stock logo
NNVC
NanoViricides
-$8.29M-$0.43N/AN/AN/AN/A-87.90%-78.69%N/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
N/AN/AN/AN/AN/A
Anchiano Therapeutics Ltd. stock logo
ANCN
Anchiano Therapeutics
N/AN/AN/AN/AN/A
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
N/AN/AN/AN/AN/A
NanoViricides, Inc. stock logo
NNVC
NanoViricides
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
N/AN/AN/A
Anchiano Therapeutics Ltd. stock logo
ANCN
Anchiano Therapeutics
N/A
3.25
3.25
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
0.22
0.79
0.26
NanoViricides, Inc. stock logo
NNVC
NanoViricides
N/A
3.44
2.47

Institutional Ownership

CompanyInstitutional Ownership
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
7.18%
Anchiano Therapeutics Ltd. stock logo
ANCN
Anchiano Therapeutics
9.05%
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
N/A
NanoViricides, Inc. stock logo
NNVC
NanoViricides
10.30%

Insider Ownership

CompanyInsider Ownership
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
0.63%
Anchiano Therapeutics Ltd. stock logo
ANCN
Anchiano Therapeutics
6.88%
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
6.40%
NanoViricides, Inc. stock logo
NNVC
NanoViricides
3.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
2059.31 million42.36 millionNot Optionable
Anchiano Therapeutics Ltd. stock logo
ANCN
Anchiano Therapeutics
167.42 millionN/ANot Optionable
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
25040.52 million15.92 millionNot Optionable
NanoViricides, Inc. stock logo
NNVC
NanoViricides
2022.98 million14.92 millionOptionable

Recent News About These Companies

NanoViricides (NYSE:NNVC) Shares Down 4.3% - What's Next?
July 30, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30929937
NanoViricides Raises Financing for Trial of Ebola Treatment, Awaits Regulatory Approval in Congo
July 28, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/nanoviricides-raises-financing-trial-ebola-130303068.html
NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the ...
July 28, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/nanoviricides-awaits-approval-dr-congo-123000434.html
NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the Trial
July 28, 2026  |  accessnewswire.comA
NanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering
July 24, 2026  |  accessnewswire.comA
As Ebola Death Toll Surpasses 930 Within Two Months, NanoViricides Has Applied to the DR Congo Regulatory Agency for Approval for a Phase II Clinical Trial of NV-387 Oral ...
July 22, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/ebola-death-toll-surpasses-930-123000376.html
As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for ...
July 13, 2026  |  oklahoman.comO
As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo
July 13, 2026  |  accessnewswire.comA
Research Analyst Report on NanoViricides Rates Company “Outperform”; Separately, A “Fireside Chat” Interview of the Company’s President Dr. Anil Diwan Hosted by Mr ...
July 8, 2026  |  usatoday.comhttps://www.usatoday.com/press-release/story/36739/research-analyst-report-on-nanoviricides-rates-company-outperform-separately-a-fireside-chat-interview-of-the-companys-president-dr-anil-diwan-hosted-by-mr-dave-donlin-was-published-by-stocki/
Research Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" Interview of the Company's President Dr. Anil Diwan Hosted by Mr. Dave Donlin ...
July 8, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/research-analyst-report-nanoviricides-rates-123000660.html
Research Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" Interview of the Company's President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily
July 8, 2026  |  accessnewswire.comA
NNVC stock in the limelight after this analyst sees a 350% upside potential – everything to know about its experimental drug for Ebola
July 6, 2026  |  msn.comhttps://www.msn.com/en-in/health/other/nnvc-stock-in-the-limelight-after-this-analyst-sees-a-350-upside-potential-everything-to-know-about-its-experimental-drug-for-ebola/ar-AA27kG1g
As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo
July 6, 2026  |  accessnewswire.comA
NanoViricides: US FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for Measles - Enables Priority Review Voucher
June 29, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-06/68891765-nanoviricides-us-fda-has-granted-a-rare-pediatric-disease-drug-designation-for-nv-387-as-a-treatment-for-measles-enables-priority-review-voucher-200.htm
US FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for Measles - Enables Priority Review Voucher
June 29, 2026  |  accessnewswire.comA
NanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo - The Oklahoman
June 23, 2026  |  oklahoman.comO
NanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo
June 22, 2026  |  accessnewswire.comA
As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of Ebola - NanoViricides Proposal is Approved by the Pillar Committee in DR ...
June 16, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/ebola-epidemic-spreads-nv-387-123000011.html
As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of Ebola – NanoViricides Proposal is Approved by the Pillar Committee in ...
June 15, 2026  |  usatoday.comhttps://www.usatoday.com/press-release/story/34804/as-the-ebola-epidemic-spreads-nv-387-oral-gummies-can-enter-a-phase-ii-clinical-trial-for-treatment-of-ebola-nanoviricides-proposal-is-approved-by-the-pillar-committee-in-dr-congo/
As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of Ebola - NanoViricides Proposal is Approved by the Pillar Committee in DR Congo
June 15, 2026  |  accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ayala Pharmaceuticals stock logo

Ayala Pharmaceuticals NASDAQ:ADXS

$0.60 0.00 (0.00%)
As of 07/31/2026

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.

Anchiano Therapeutics stock logo

Anchiano Therapeutics NASDAQ:ANCN

Anchiano Therapeutics Ltd., a preclinical biotechnology company, discovers, develops, and commercializes small molecule anti-cancer therapies. It primarily develops Pan-RAS Program that identifies novel indene-based small molecules that exhibit potent and selective inhibition of activated RAS signaling regardless of isoform or mutation; and PDE10/Ã-catenin program, which identifies small molecules that selectively and potently inhibit PDE10 and suppress Wnt/APC/Ã-catenin signaling in preclinical models. Anchiano Therapeutics Ltd. has collaboration and license agreement with ADT Pharmaceuticals, LLC to research and develop programs related to the pan-RAS and PDE10/Ã-catenin programs. The company was formerly known as BioCancell Ltd. and changed its name Anchiano Therapeutics Ltd. in July 2018. Anchiano Therapeutics Ltd. was founded in 2004 and is headquartered in Cambridge, Massachusetts.

China Pharma stock logo

China Pharma NYSE:CPHI

$1.11 0.00 (0.00%)
Closing price 07/31/2026 04:00 PM Eastern
Extended Trading
$1.12 +0.01 (+0.81%)
As of 07/31/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. In addition, the company provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. Further it offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Additionally, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It offers its products through distributors, its network of sales offices, and sales representatives. The company is based in Haikou, the People's Republic of China.

NanoViricides stock logo

NanoViricides NYSE:NNVC

$1.52 0.00 (0.00%)
Closing price 07/31/2026 04:00 PM Eastern
Extended Trading
$1.56 +0.04 (+2.37%)
As of 07/31/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas